{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T22:23:46Z","timestamp":1780957426971,"version":"3.54.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","contraceptionjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contraception"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.contraception.2020.06.006","type":"journal-article","created":{"date-parts":[[2020,6,20]],"date-time":"2020-06-20T07:00:39Z","timestamp":1592636439000},"page":"237-242","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ovulation inhibition with a new vaginal ring containing trimegestone"],"prefix":"10.1016","volume":"102","author":[{"given":"Ingrid J.M.","family":"Duijkers","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Klipping","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Draeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara S.","family":"Schug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Dax","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maika","family":"Friedrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Klaus","family":"Nickisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.contraception.2020.06.006_b0005","series-title":"Medical eligibility criteria for contraceptive use: a WHO family planning cornerstone","author":"World Health Organization","year":"2010"},{"key":"10.1016\/j.contraception.2020.06.006_b0010","doi-asserted-by":"crossref","unstructured":"World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception 1998;57:315-324.","DOI":"10.1016\/S0010-7824(98)00041-9"},{"key":"10.1016\/j.contraception.2020.06.006_b0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3109\/13625189909064007","article-title":"Oral progestogen-only contraceptives and cardiovascular risk: results from the Transnational Study on Oral Contraceptives and the health of Young Women","volume":"4","author":"Heinemann","year":"1999","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2020.06.006_b0020","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1016\/S0140-6736(99)04394-9","article-title":"Risk of idiopathic venous thromboembolism in users of progestogens alone","volume":"354","author":"Vasilakis","year":"1999","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1016\/j.contraception.2020.06.006_b0025","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/0010-7824(94)90113-9","article-title":"Progestin-only oral contraception: a comprehensive review","volume":"50","author":"McCann","year":"1994","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.06.006_b0030","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1093\/humrep\/14.4.982","article-title":"A comparison of the inhibition of ovulation achieved by desogestrel 75 \u00b5g and levonorgestrel 30 \u00b5g daily","volume":"14","author":"Rice","year":"1999","journal-title":"Hum Reprod"},{"key":"10.1016\/j.contraception.2020.06.006_b0035","doi-asserted-by":"crossref","unstructured":"Collaborative Study Group on the Desogestrel-containing Progestogen-only Pill. A double-blind study comparing the contraceptive efficacy, acceptability and safety of two progestogen-only pills containing desogestrel 75 \u00b5g\/day or levonorgestrel 30 \u00b5g\/day. Eur J Contracept Reprod Health Care 1998;3:169-178.","DOI":"10.3109\/13625189809167250"},{"key":"10.1016\/j.contraception.2020.06.006_b0040","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1783\/147118902101196784","article-title":"Bleeding problems and progestogen-only contraception","volume":"28","author":"Porter","year":"2002","journal-title":"J Fam Plann Reprod Health Care"},{"key":"10.1016\/j.contraception.2020.06.006_b0045","doi-asserted-by":"crossref","unstructured":"Grimes DA, Lopez LM, O\u2019Brien PA, Raymond EG. Progestin-only pills for contraception. Cochrane Database Syst Rev 2013;11:CD007541.","DOI":"10.1002\/14651858.CD007541.pub3"},{"key":"10.1016\/j.contraception.2020.06.006_b0050","doi-asserted-by":"crossref","first-page":"419","DOI":"10.3109\/13625187.2015.1044082","article-title":"A randomised study comparing the effect on ovarian activity of a progestogen-only pill (POP) containing desogestrel and a new POP containing drospirenone in a 24\/4 regimen","volume":"20","author":"Duijkers","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.contraception.2020.06.006_b0055","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.contraception.2015.07.014","article-title":"Drospirenone-only contraceptive: results from a multicentre comparative trial of efficacy, safety and tolerability","volume":"92","author":"Archer","year":"2015","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.06.006_b0060","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1016\/S0039-128X(03)00142-9","article-title":"The preclinical biology of a new potent and selective progestin: trimegestone","volume":"68","author":"Wenneker","year":"2003","journal-title":"Steroids"},{"key":"10.1016\/j.contraception.2020.06.006_b0065","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1080\/09513590701267727","article-title":"Preclinical and clinical properties of trimegestone: a potent and selective progestin","volume":"23","author":"Sitruk-Ware","year":"2007","journal-title":"Gynecol Endocrinol"},{"key":"10.1016\/j.contraception.2020.06.006_b0070","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/0010-7824(93)90025-3","article-title":"Ultrasound evaluation of ovarian activity under oral contraceptives","volume":"47","author":"Hoogland","year":"1993","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.06.006_b0075","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/0010-7824(80)90142-0","article-title":"Hormonal effects of the 300 \u00b5g norethisterone (NET) minipill. 1. Daily steroid levels in 43 subjects during a pretreatment cycle and during the second month of NET administration","volume":"21","author":"Landgren","year":"1980","journal-title":"Contraception"},{"key":"10.1016\/j.contraception.2020.06.006_b0080","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/0002-9378(92)91706-G","article-title":"Hormone treatment of endometriosis: the estrogen threshold hypothesis","volume":"166","author":"Barbieri","year":"1992","journal-title":"Am J Obstet Gynecol"},{"issue":"1","key":"10.1016\/j.contraception.2020.06.006_b0085","article-title":"Integrated pharmacometrics and systems pharmacology model-based analysis to guide GnRH receptor modulator development for management of endometriosis","volume":"17","author":"Riggs","year":"2012","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"10.1016\/j.contraception.2020.06.006_b0090","doi-asserted-by":"crossref","unstructured":"Hadji P, Colli E, Regidor P-A. Bone health in estrogen-free contraception. Osteoporos Int 2019. Published online: https:\/\/doi.org\/10.1007\/s00198-019-05103-6.","DOI":"10.1007\/s00198-019-05103-6"}],"container-title":["Contraception"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420301839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0010782420301839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T20:16:33Z","timestamp":1757880993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0010782420301839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S0010782420301839"],"URL":"https:\/\/doi.org\/10.1016\/j.contraception.2020.06.006","relation":{},"ISSN":["0010-7824"],"issn-type":[{"value":"0010-7824","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovulation inhibition with a new vaginal ring containing trimegestone","name":"articletitle","label":"Article Title"},{"value":"Contraception","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.contraception.2020.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}